Background-Atrial fibrillation is the most common sustained cardiac arrhythmia in adults. We hypothesized that gain-offunction KCNQ1 mutations previously associated with familial atrial fibrillation have distinct pharmacological properties that may enable targeted inhibition. Methods and Results-Wild-type (WT) KCNQ1 or the familial atrial fibrillation mutation KCNQ1-S140G was heterologously coexpressed with KCNE1 to enable electrophysiological recording of the slow delayed rectifier current (I Ks ) and investigation of pharmacological effects of the I Ks selective blocker HMR-1556. Coexpression of KCNQ1-S140G with KCNE1 generated potassium currents (S140G-I Ks ) that exhibited greater sensitivity to HMR-1556 than WT-I Ks . Enhanced HMR-1556 sensitivity was also observed for another gain-of-function atrial fibrillation mutation, KCNQ1-V141M. Heteromeric expression of KCNE1 with both KCNQ1-WT and KCNQ1-S140G generated currents (HET-I Ks ) with gain-of-function features, including larger amplitude, a constitutively active component, hyperpolarized voltage dependence of activation, and extremely slow deactivation. A low concentration of HMR-1556, which had little effect on WT-I Ks but was capable of inhibiting the mutant channel, reduced both instantaneous and steady state HET-I Ks to levels that were not significantly different from WT-I Ks and attenuated use-dependent accumulation of the current. In cultured adult rabbit left atrial myocytes, expression of S140G-I Ks shortened action potential duration compared with WT-I Ks . Application of HMR-1556 mitigated S140G-I Ks -induced action potential duration shortening and did not alter action potential duration in cells expressing WT-I Ks . Conclusions-The enhanced sensitivity of KCNQ1 gain-of-function mutations for HMR-1556 suggests the possibility of selective therapeutic targeting, and, therefore, our data illustrate a potential proof of principle for genotype-specific treatment of this heritable arrhythmia. (Circ Arrhythm Electrophysiol. 2013;6:960-966.) (J.D.C.). The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/
A trial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults. The prevalence of AF rises exponentially with age, and because of the aging population, the number of people with AF in the United States is projected to increase to 12 million by 2050. 1 Importantly, AF confers a 6-fold increased risk for thromboembolic disease including stroke, predisposes to heart failure, and is associated with premature death. 2 The incremental healthcare costs directly related to the diagnosis and management of AF in the United States have been estimated at $6 billion. 3 
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Most often, AF occurs within the context of structural heart disease with onset after 65 years of age. However, an estimated 10% to 30% of AF, designated as lone AF, arises in the absence of overt heart disease and has a younger age of onset. [4] [5] [6] [7] Genetic predisposition to AF has been demonstrated in populations 8, 9 and families with monogenic forms of the disease. 10 AF-associated mutations have been identified in potassium channels, [11] [12] [13] [14] [15] [16] sodium channels, [17] [18] [19] and other genes. 20 The mutation KCNQ1-S140G was the first identified mutation and remains the best-studied genetic variant associated with autosomal dominant AF. 11, [21] [22] [23] KCNQ1 encodes a pore-forming voltage-gated potassium channel (Kv7.1 or KCNQ1) that combines with the auxiliary subunit KCNE1 to generate the slow component of the delayed rectifier potassium current (I Ks ), critical for cardiac action potential repolarization. Coexpression of KCNQ1-S140G with KCNE1 (S140G-I Ks ) demonstrated a gain of function with larger and more instantaneous current activation. 11, 23 A similar gain-offunction effect occurs with the AF-associated mutation KCNQ1-V141M. 12 These in vitro data are consistent with the notion that increased repolarizing potassium current evoked by these mutations causes shortening of atrial action potentials in myocytes and an abbreviated effective refractory period in atrial tissues, resulting in an increased probability of re-entry circuits and AF. 23 We hypothesized that KCNQ1 gain-of-function mutations have pharmacological properties distinct from the wild-type (WT) channel that may enable selective inhibition of mutant channel complexes. Pharmacological targeting of this gain-offunction behavior would be predicted to decrease AF susceptibility in people with this dominant mutant allele. We tested this hypothesis using the chromanol 293B derivative HMR-1556, a highly specific I Ks blocker when used at low concentrations. Here, we present evidence that S140G-I Ks and V141M-I Ks exhibit enhanced sensitivity to HMR-1556 because of an additional highaffinity state. Using a concentration that predominantly inhibits the high-affinity state, HMR-1556 effectively suppressed S140G-I Ks amplitudes to levels not different from WT-I Ks , attenuated the use-dependent accumulation of current without significant effects on WT-I Ks , and mitigated action potential shortening in cultured adult rabbit left atrial myocytes without affecting WT-I Ks action potential duration (APD). These data suggest a potential opportunity for genotype-specific treatment of familial AF.
Methods
Voltage clamp experiments were performed in Chinese hamster ovary cells transiently transfected with plasmids containing potassium channel subunits (KCNQ1, KCNE1) constructed in plasmids coexpressing a transfection marker (dsRedMST, enhanced green fluorescent protein, or CD8). Recordings were performed in the absence or presence of HMR-1556. Current clamp recordings were performed with cultured adult rabbit left atrial myocytes infected with adenoviruses encoding WT or mutant KCNQ1 subunits, in combination with a separate adenovirus encoding KCNE1. Action potentials were elicited from transduced myocytes using whole-cell patch clamp 48 to 72 hours after isolation in the absence or presence of HMR-1556.
Differences between the 2 groups were assessed using unpaired Student t test. When comparing >2 groups, 1-way ANOVA followed by a Tukey post hoc test was performed on values obtained for a given membrane voltage. Statistical tests were performed using SigmaStat 2.03 (Systat Software, Inc, Chicago, IL). Significance levels are reported as 2-sided P values. A complete description of all experimental methods is presented in the online-only Data Supplement.
Results

S140G-I Ks Exhibits Enhanced Sensitivity to HMR-1556
We tested whether heterologously expressed I Ks channel complexes consisting of either WT or mutant (S140G) KCNQ1 subunits, in combination with the auxiliary subunit KCNE1, are inhibited by HMR-1556. Whole-cell recordings of Chinese hamster ovary cells transfected with S140G and KCNE1 (S140G-I Ks ) demonstrated nearly instantaneous activation of outward current in contrast to the slowly activating current observed in cells expressing WT-I Ks (Figure 1A and 1B). Because KCNQ1-S140G mutation-positive subjects were reported to be heterozygous in familial AF and because WT and mutant KCNQ1 subunits can coassemble in heteromeric channels, we examined channel complexes consisting of both WT and mutant subunits coexpressed with KCNE1 (HET-I Ks ), which exhibited larger amplitudes with a large fraction of instantaneous current ( Figure 1C Figure 1 . S140G-I Ks and HET-I Ks exhibit enhanced sensitivity to HMR-1556. Representative current recordings from cells expressing wildtype (WT)-I Ks (A), S140G-I Ks (B), or HET-I Ks (C). Recordings illustrated in A, B, and C were obtained using the activation protocol described in the Methods section. Average current densities (current normalized to cell capacitance) elicited by a 2-second voltage step to +40 mV followed by a 10-second interpulse during application of vehicle or various concentration of HMR-1556 from cells expressing WT-I Ks (D), S140G-I Ks (E), or HET-I Ks (F). Current density traces in D, E, and F are averages from 9 to 11 cells. complexes activated by low-frequency pulsing (10-second interpulse duration) to +40 mV ( Figure 1D-1F ). However, inhibition of S140G-I Ks and HET-I Ks was more pronounced than WT-I Ks at lower concentrations.
We assessed concentration-response relationships for WT-I Ks , S140G-I Ks , and HET-I Ks to determine whether the channel complexes have different affinities for HMR-1556 ( Figure 2 ). Cells expressing WT-I Ks exhibited a concentrationresponse curve that was fit by the Hill equation, yielding an IC 50 of 214 nmol/L and Hill coefficient of 1.2. In contrast, S140G-I Ks exhibited a complex concentration-response that suggested 2 affinity states. The IC 50 of the high-affinity state was 3.7 nmol/L, whereas the low-affinity state had an IC 50 of 97.7 nmol/L. Both states were significantly different from the IC 50 for WT-I Ks (P<0.001). Hill coefficients for the highaffinity (2.2) and low-affinity (2.5) states on S140G-I Ks suggested positive cooperative binding of the drug. The gating kinetics of the current sensitive to 30 nmol/L HMR-1556, a concentration near the crux between the 2 affinity states on the concentration-response curve, was not overtly different than the drug-insensitive current ( Figure There were also substantial differences in the kinetics of HMR-1556 inhibition. Specifically, on-and off-rates observed for suppression of S140G-I Ks were significantly slower than WT-I Ks ( Figure II in the online-only Data Supplement). The dramatically slower off-rate for S140G-I Ks suggested a stronger interaction between HMR-1556 and the channel consistent with our finding that the mutant subunit confers an enhanced affinity for the drug. The intermediate phenotype of HET-I Ks exhibited an on-rate comparable with WT-I Ks but a significantly slower off-rate that was more similar to S140G-I Ks . This enhanced sensitivity suggested an opportunity to suppress the mutant current, with minimal effects selectively on WT-I Ks .
V141M-I Ks Exhibits Enhanced Sensitivity to HMR-1556
We also determined the pharmacological effects of HMR-1556 on another previously reported gain-of-function KCNQ1 mutation, V141M, associated with early-onset AF. 12 V141M-I Ks exhibited enhanced sensitivity to HMR-1556 and a complex IC 50 binding curve with values similar to S140G-I Ks (Figure 3 ). The off-rate was significantly slower than WT-I Ks ( Figure II in the online-only Data Supplement). These data demonstrate that increased HMR-1556 sensitivity was not specific to S140G-I Ks . All further experiments were conducted with S140G-I Ks as a prototypic familial AF mutation. During repetitive depolarization to +40 mV with a short recovery period, both WT-I Ks and HET-I Ks exhibited a usedependent accumulation of instantaneous and steady state current over time, but HET-I Ks current density was significantly greater than WT-I Ks at each successive pulse ( Figure IV in the online-only Data Supplement). The ratio of instantaneous to steady state current at the end of this protocol, a proxy for the degree of constitutive activation, was much greater for HET-I Ks (84±3%) than WT-I Ks (38±4%; P<0.001). These findings illustrate the dynamic nature of I Ks and further emphasize the biophysical consequences of the gain-of-function mutation, KCNQ1-S140G.
Properties of Heteromeric S140G-I Ks and WT-I Ks
Selective Inhibition of HET-I Ks With HMR-1556
Given the enhanced sensitivity of S140G-I Ks to HMR-1556, we hypothesized that HET-I Ks could be selectively suppressed by using a concentration of HMR-1556 that predominantly inhibits the high-affinity state. To test this hypothesis, we applied 20 nmol/L HMR-1556 or vehicle to channels heterologously expressed and assessed the effects of drug on gating kinetics and current amplitudes.
Vehicle had no effects on the behavior of WT-I Ks and HET-I Ks (Figure 4A and 4B ). Furthermore, 20 nmol/L HMR-1556 had no appreciable effect on current levels or gating behavior of WT-I Ks (Figure 4C ), but the drug exerted notable effects on HET-I Ks , including suppression of both instantaneous and steady state current amplitude and attenuation of usedependent current accumulation ( Figure 4D ). The effects of 20 nmol/L HMR-1556 on WT-I Ks and HET-I Ks are quantified in Figure 5A -5D. Importantly, 20 nmol/L HMR-1556 did not inhibit WT-I Ks but did reduce the amplitude of HET-I Ks to levels that were not significantly different (P=0.32) from WT-I Ks . In addition, the ratio of instantaneous to steady state current for HET-I Ks was also modified by the drug to a value that was not significantly different from WT-I Ks (P=0.06; Figure 5E ). These findings demonstrated the selective suppression of HET-I Ks and the normalization of this mutant current to WT-I Ks levels.
HMR-1556 Mitigates S140G-I Ks -Induced Atrial APD Shortening
We examined the effects of HMR-1556 on action potentials in cultured adult rabbit left atrial myocytes expressing WT-I Ks or S140G-I Ks channel complexes. Action potentials were elicited at 1 Hz during whole-cell current clamp recording of adenovirus-transduced atrial myocytes ( Figure V in the onlineonly Data Supplement). Expression of S140G-I Ks in left atrial myocytes hyperpolarized the resting membrane potential and significantly reduced APD at 90% compared with WT-I Ks expression (APD at 90%: WT-I Ks , 177.4±21.0 ms; S140G-I Ks , 68.9±19.2 ms; P<0.001; Figure 6A ). Application of 1 µmol/L Figure 3 . V141M-I Ks exhibits enhanced sensitivity to HMR-1556. A, Representative current densities (current normalized to cell capacitance) recorded from cells expressing wild-type (WT)-I Ks that were elicited by a 2-second voltage step to +40 mV followed by a 10-second interpulse during application of vehicle or various concentrations of HMR-1556. B, HMR-1556 concentration-response curves for V141M-I Ks (▲) and WT-I Ks (○). Solid lines represent fits of the averaged data (9-11 cells) to a biphasic Hill function (online-only Data Supplement material). For V141M-I Ks , the high-affinity state had an IC 50 of 0.72 nmol/L and Hill coefficient of 0.6; the low-affinity state had an IC 50 of 204 nmol/L and Hill coefficient of 1.7. October 2013 HMR-1556 did not alter APD at 90% of WT-I Ks -expressing myocytes (185.2±27.3 ms; P=0.59), whereas application of 1 µmol/L HMR-1556 significantly lengthened APD at 90% of S140G-I Ks -expressing myocytes (117.1±12.7 ms; P<0.04; Figure 6B ). These findings illustrate that HMR-1556 can selectively suppress the effects of S140G-I Ks on atrial APD without altering action potentials in myocytes expressing WT-I Ks .
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Discussion
The discovery of mutations in familial AF illustrated the contribution of specific genetic factors to AF susceptibility and suggested molecular mechanisms for some heritable forms of this common arrhythmia. For gain-of-function KCNQ1 mutations in particular, we sought to exploit this knowledge to explore a potential targeted therapy. Specifically, we hypothesized that KCNQ1 mutations predisposing to AF encode potassium channels with distinct pharmacological properties that could render them susceptible to selective inhibition. Genotype-specific therapies for inherited arrhythmia syndromes, such as congenital long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia, are emerging. 24, 25 Furthermore, a precedent for mutation-specific pharmacology of Figure 6 . HMR-1556 mitigates atrial action potential shortening by S140G-I Ks . Representative averages of 10 sequential action potentials from cultured rabbit left atrial myocytes expressing either wild-type (WT)-I Ks (black line, n=6) or S140G-I Ks (blue line, n=6). A, Action potentials elicited after application of vehicle. B, Action potentials elicited after application of 1 µmol/L HMR-1556. Values of action potential duration at 90% are provided in the text. a rare, inherited disorder was established by the approval of ivacaftor for treatment of cystic fibrosis. 26 In this study, we investigated the use of the selective and high-affinity I Ks blocker HMR-1556 to inhibit gain-of-function KCNQ1 mutations S140G and V141M. Chromanol 293B was the first identified selective I Ks blocker, which exerts its effect at low micromolar concentrations. 27 The chromanol derivative HMR-1556 was developed to increase potency and improve the selectivity of I Ks inhibition. 28 This derivative was initially demonstrated to have an IC 50 of 120 nmol/L against I Ks expressed in Xenopus oocytes with little effect on other recombinant potassium channels at 10 µmol/L consistent with a high level of specificity. 28 In isolated canine ventricular myocytes, HMR-1556 inhibits I Ks with a nanomolar IC 50 , whereas inhibition of other ionic currents (eg, I Kr , I K1 , I to , I Ca,L ) required much higher concentrations. 29 Consistent with our hypothesis, we observed that S140G-I Ks exhibits enhanced sensitivity to HMR-1556. This enhancement was correlated with the emergence of an additional high-affinity state, which was also observed with V141M-I Ks. Importantly, using a concentration that predominantly inhibits the high-affinity state, we demonstrated that HMR-1556 effectively suppressed HET-I Ks amplitude to a level that was not significantly different from WT-I Ks . Furthermore, this drug concentration attenuated the use-dependent accumulation of HET-I Ks that occurs during repetitive pulsing. Importantly, we demonstrated that HMR-1556 can mitigate the S140G-I Ks -induced APD shortening in cultured adult rabbit atrial myocytes without affecting action potentials in myocytes expressing WT-I Ks . These findings offer evidence supporting the potential for genotype-specific therapy of familial AF.
The potential use of HMR-1556 or a similarly acting drug in the setting of familial AF should be considered in the context of the liabilities of inhibiting I Ks in tissues other than atria. Reduction of I Ks in ventricular muscle carries the risk of reduced repolarization reserve and predisposition to re-entrant arrhythmia as in type 1 congenital long-QT syndrome. In anesthetized dogs receiving continuous intravenous infusions of HMR-1556, there was significant QTc prolongation and reproducible triggering of torsades de points with an isoproterenol bolus. 30 Prolongation of QTc during HMR-1556 exposure is accentuated in dogs by coadministration of the I Kr blocker dofetilide. 31 In Langendorff-perfused rabbit hearts, HMR-1556 alone was not sufficient to prolong monophasic APD, but coadministration of either dofetilide alone or dofetilide with veratridine caused significant lengthening of APD. 32, 33 These reports emphasize the potential proarrhythmic effects of high concentration of HMR-1556 or of concurrent I Ks and I Kr inhibition. Fortunately, our data indicate that selective inhibition of S140G-I Ks can be achieved at HMR-1556 concentrations that do not suppress WT-I Ks .
Ototoxicity is another potential concern with HMR-1556. Because I Ks expressed in the stria vascularis of inner ear is important in the generation of the K + -rich cochlear endolymph, disruption of I Ks has the potential to impair hearing as observed in autosomal-recessive Jervell-Lange-Nielsen syndrome associated with KCNQ1 or KCNE1 mutations. [34] [35] [36] Indeed, high concentrations of HMR-1556 exert a reversible ototoxicity in cats. 37 Again, our data suggest that there is a potential concentration range that may be free of inner ear adverse effects.
In summary, the AF-associated mutations KCNQ1-S140G and KCNQ1-V141M confer enhanced sensitivity to HMR-1556 in the context of the I Ks channel complex. At a concentration that predominantly suppresses current by interacting with a novel high-affinity state expressed by the S140G mutant, HMR-1556 normalized current amplitudes to levels that are not significantly different from WT-I Ks and attenuated the use-dependent accumulation of current. In cultured adult rabbit atrial myocytes, HMR-1556 mitigated the shortened APD induced by S140G-I Ks expression. Our demonstration of selective targeting of this gain-of-function mutation provides a potential proof of principle for genotype-specific treatment of familial AF.
